贵州省健康医药产业高质量发展实施方案（2026-2030年）（征求意见

Intake

Announced: 2026-10-20
Implementer: Provincial · 贵州省 · 贵州省人民政府
Guizhou Provincial People's Government
Found: 1 measure

Measure	Favours	From	To
Capital grant	Chinese firms or production in China; Local firms	from doc	—

On 20 October 2026, the Guizhou Provincial People's Government (贵州省人民政府; provincial level, Guizhou) issued opinions, 《贵州省健康医药产业高质量发展实施方案（2026-2030年）（征求意见》 ("Implementation Plan for the High-Quality Development of the Health and Pharmaceutical Industry in Guizhou Province (2026–2030) (Draft for Public Consultation)"). Measures: capital grant (favouring Chinese firms or production in China and local firms). [Draft from a keyword screen: check each measure against the text.]

CSV rows for this document · JSON · one line per measure, with sources and mirrors. Keyword screen: confirm each against the text.

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 56 relationships

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 44,848,528

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 462,922,538

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 1,192,805,937

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 808,524,769

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 14,709,823

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 51,914,199

Barbados: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 11,048,755

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 484,138,906

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,404,452,581

Costa Rica: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 679,629,844

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 1,767,794

Czech Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 109,265,516

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 9,263,991,826

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 1,518,413,247

Dominican Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 189,707,073

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 796,050,101

Estonia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 1,561,282

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 280,884,380

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 2,916,196,065

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 1,186,006,623

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 319,150,106

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 518,882,101

Croatia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,553,715

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 89,893,730

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 21,771,642

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 251,382,896

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 5,989,195,558

Iceland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,160,561

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 364,615,606

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 3,423,459,146

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 3,394,502,575

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 721,161,945

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,951,745

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 2,492,680,500

Malaysia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 322,159,283

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 958,178,104

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 35,186,060

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 53,580,941

Pakistan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 11,230,821

Philippines: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 11,421,406

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 114,462,673

Portugal: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 9,093,537

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 28,726,085

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,999,718

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 485,064,513

Slovak Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 4,015,111

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 215,702,960

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 2,103,958,137

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 123,898,564

Turkey: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 63,932,495

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 356,327,314

Uruguay: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 14,508,770

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 10,401,223,459

Vietnam: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 487,562,927

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2025 trade; broad sector headings; computed, not analyst-reviewed · intervention 61250 · recorded trade USD 18,425,637

Implementing jurisdiction: China · intervention 61250

Assessment states

Trade-based partners recorded

Measures

Capital grant

Provincial · origin: Chinese firms or production in China · locality: Local firms · CPC 352; 481 · Keyword screen (unreviewed)

Implemented by China (subnational) · affects 55 partners (inferred from trade data, 2025 trade): United States, Germany, Ireland, Switzerland, Italy, Japan …

统筹使用省级财政资金，对我省首次获得药品注册批件的创新药、首次获得生产批件的第三类创新医疗器械和第二类创新医疗器械，以及通过一致性评价的仿制药，给予企业奖励支持。

Supports production in a place, so favours that place by rule.

Same central policy, other provinces

工业和信息化部等七部门关于印发《医药工业数智化转型实施方案（2025—2030年）》的通知 · 工信部联消费〔2025〕79号 · 2025-04-03 · answered in 1 province held · trace it ↗

Province	First document citing it	Dated	Lag
Guizhou	this document	2026-10-20	565 d

Held documents only: these are counts of what we have collected, not of what each province issued.

Full text

贵州省健康医药产业高质量发展实施方案（2026-2030年）（征求意见稿）健康医药产业是贵州特色优势产业，在保障人民健康、推动经济发展等方面具有重要作用。为深入贯彻省委、省政府关于发展壮大健康医药产业的决策部署，落实工业和信息化部等部门印发的《医药工业数智化转型实施方案（2025—2030年）》《中药工业高质量发展实施方案（2026—2030年）》，加快提升产业链供应链韧性和稳定性，增强供应保障能力，促进健康医药产业高质量发展，制定本方案。一、总体要求以习近平新时代中国特色社会主义思想为指导，认真贯彻党的二十大和二十届历次全会精神，全面落实习近平总书记在贵州考察时的重要讲话精神，紧紧围绕人民群众日益增长的健康需求，深入实施强化比较优势战略，坚持守正创新、特色引领、融合发展、重点突破，以健康医药产业上下游深度融合为着力点，更加突出健康价值创造，大力实施“增品种、提品质、创品牌”专项行动，加快推进数智化转型和绿色化升级，推动产业结构持续优化、发展质效显著提升。到2030年，全省健康医药产业总产值达到500亿元，培育 10亿级以上医药大单品10个，创建先进级智能工厂20个、省级绿色工厂20个，建设一批高标准中药原料生产基地，打造一批引领带动能力突出的优强医药企业和消费名品，培育一批“中医药+”大健康典型示范消费场景，健康医药全产业链协同发展体系初步形成。二、重点任务（一）实施集聚集约发展行动 1.优化产业发展布局。支持贵阳市聚焦乌当、息烽、花溪等地集中布局医药制造项目，推动“两药一械”（即中成药、化学药、医疗器械）全产业链发展，积极培育生物医药项目，加快发展大健康新产品新业态，打造健康医药研发制造核心引领区。支持安顺市、黔南州壮大提升中药民族药产业，精深发展中药材加工、中药制剂生产，做优“中医药+康养”试点示范项目，建设以中医药为核心的健康医药重点集聚区。支持遵义、铜仁、黔东南、黔西南等地发挥区域资源优势，依托优强企业发展壮大中成药大单品、道地药材种植及加工、药食同源等产品，建设错位发展、协同互补的健康医药特色支撑区。 2.突出发展特色产业。充分挖掘苗药等民族药资源，大力推进中药新药研发和医疗机构制剂成果转化，支持中成药大品种开展工艺优化、质量标准提升及新适应症研究等二次开发，做优做强中成药产业。强化道地药材应用，围绕“贵药”大品种精准定位核心单品，创新发展破壁饮片、冻干饮片及中药配方颗粒等新型饮片，培育打造中药饮片优质大品种。积极发展高附加值含磷、含氟、含碘医药中间体与特色原料药，支持企业重点布局高端“首仿药”，优化提升化学仿制药产品结构，做大化学药产业规模。聚焦血液制品、细胞治疗等领域加快发展生药医药，着力培育抗体药物、多肽药物、核酸药物等生物技术新药。推动医用敷料、卫生材料、义齿加工等医疗器械向高附加值发展，依托算力资源引进培育智能诊疗设备、云端医疗平台等产品。以药食同源为核心融合发展大健康产业，培育打造“贵药膳”“贵药饮”等区域品牌，大力发展保健食品、中药日化用品、药浴包、香药草等精深加工产品，拓展康养旅居业态，推进“中医药+保健产业”融合发展。 3.建强医药产业园区。引导医药产业园区推行“一园区一主业、一赛道一园中园”模式，瞄准细分领域打造中药民族药创新园、化学原料药园、医疗器械园、中药材加工特色园中园等专业园区，有序退出“小、散、杂”低效园区。推动医药产业园区实施专业化升级和全链条配套，聚焦主业补齐集中式纯水站、危废集中处置、医药冷链仓储等专用公用设施，建设药物发现、药效安评、质量检验、中试放大等公共技术服务平台，联合高校、科研院所、医疗机构培育创建药物临床试验合作中心等载体，不断提升园区承载能力。（二）实施研发创新赋能行动 4.加强研发创新平台建设。强化中药功效成分发掘与利用全国重点实验室、国家苗药工程技术研究中心、现代苗药创制技术国家地方联合工程研究中心、国家企业技术中心等重大创新平台建设，推动科研成果加快落地转化。围绕中药民族药、化学药仿创、生物制药、医疗器械、中药材资源五大赛道，分类建设省级重点实验室、工程技术研究中心、概念验证中心、中试基地等平台。整合集聚创新资源，组织医药企业、医疗机构、高校、科研机构等联合建设中药工业守正创新中心，聚焦现代临床前沿需求，围绕中药新药研发、医疗机构中药制剂转化、有效成分提取分离等产业技术瓶颈开展协同攻关。支持有条件医药企业或医疗机构牵头建设区域医疗机构制剂中心，提供制剂研发、委托配制、代煎代配等服务。 5.强化创新药械研发支持。深化政产学研医协同创新机制，支持以企业为主导，与高校、科研院所、医疗机构、园区平台等组建创新药械研发联合体，申报实施国家重大新药创制、省级重点研发计划。深入挖掘在临床上具有独特优势的医疗机构中药民族药制剂品种，加大政策支持，加快医疗机构制剂向新药转化。统筹使用省级财政资金，对我省首次获得药品注册批件的创新药、首次获得生产批件的第三类创新医疗器械和第二类创新医疗器械，以及通过一致性评价的仿制药，给予企业奖励支持。 6.优化创新药械审评审批服务。加强创新药械注册审评沟通机制，支持在重点医药园区开展药品监管驻园服务，按照“提前介入、一企一策、全程辅导”的原则进行申报指导。提升审评审批效率，创新药药品注册检验每批次用量从全检用量的3倍减为2倍，药品注册检验时限缩短10个工作日，第二类创新医疗器械审评审批时限由42个工作日缩短至35个工作日。完善容缺办理制度，对市场前景好、临床价值高的新优药械，推行上市许可持有人转让落户我省实行容缺审批，对企业入驻医药园区变更中药品种生产地址实行承诺制容缺办理。 7.促进创新药械临床应用推广。动态编制新优药械目录，对符合条件的新优药械实行随时申报、及时挂网，指导医保定点医疗机构结合临床需求，按照“应配尽配”原则及时纳入用药目录或用械目录。符合条件的新优药械品种，不纳入门诊次均费用、门诊次均药品费用、住院次均费用等公立医院绩效指标监测范围。鼓励行业学（协）会、医疗机构开展创新药械临床使用培训，指导医师合理使用。加强医保体系对创新产品应用的支撑，合理确定创新药品医疗器械医保支付标准。（三）实施制造能力升级行动 8.加快推进数智化转型。支持医药企业建立数智化转型“一把手”负责制，将数智化转型贯穿药品生产销售等全生命周期，重点实施生产、质控、检验、调配等核心环节数智化改造，鼓励有条件的企业上线智能产线、AI 质量管控、数字车间，推动人工智能技术深度赋能创新药械研发全流程，建设一批先进级智能工厂，争创一批卓越级智能工厂。加大中小药企数智化转型评估诊断服务，引导中小药企实施轻量化改造，推广低成本MES（生产执行系统）、电子批记录、在线质检、药品追溯等系统，不断完善健康医药产业数智化转型生态。 9.全面推动绿色化发展。引导医药企业加快实施绿色化改造，鼓励企业推广应用余热回收、节水循环、溶剂回收、连续低温萃取等技术和装置，有序淘汰低效提取、高污染反应设备，支持企业建设溶剂回收中心等装置，推行医药固废、药渣资源化综合利用，培育一批绿色化转型标杆企业，创建一批国家级、省级绿色工厂。支持医药产业园区打造循环化绿色园区，集中布局污水处理、危废集中处置共享设施，降低中小药企环保运维成本。推动链主企业开放绿色工艺、环保设施，带动上下游配套企业同步清洁生产。 10.提升关键技术和质量标准。聚焦“贵药”大品种和道地优势药材，加快制修订中药材生产加工关键环节生产技术规范和质量标准，按照“标准+认证”模式推动质量分级管理，扩大产品定价权。健全完善中药饮片炮制规范、中药配方颗粒质量标准，强化标准引领提升专业化、规模化生产，促进饮片生产提质降本增效。加强中成药二次开发的跟踪培育指导，支持企业改进提升生产工艺和制剂技术，加快推动中成药重点品种地方标准升级为国家标准。鼓励行业组织、龙头企业等建设并推广中药质量追溯信息管理体系，促进中药生产流通等全流程关键信息互联互通与数据共享。（四）实施中药原料提质行动 11.加强良种繁育。依托省药用植物繁育与种植重点实验室、省农作物品种资源研究所等科研平台，建立健全中药材种子保护、繁育、研发、推广标准化体系。深入推进中药材民族药材资源保护和开发利用，支持医药企业与科研院所共建良种繁育实验室，加快推进道地药材提纯复壮和新品种选育，开展良种繁育技术攻关，建设一批道地、特色中药材良种繁育基地。 12.强化规范种植。优化中药材产业布局，重点围绕“贵药”大品种推进中药材产业集群化发展，提升道地药材“一县一业、多县一群”的特色优势。支持优势品种中药材建立中药材种植技术规程，推广中药材生态种养、野生抚育和仿野生栽培技术，塑造“黔地灵药”优质优价发展优势。引导医药企业聚焦重点中药原料品种，围绕主产区做优“定制药园”、GAP（中药材生产质量管理规范）基地，打造高标准中药原料生产基地。 13.提升产地初加工水平。支持医药企业在“定制药园”、GAP基地配套建设产地初加工（含趁鲜切制）工厂，建设推广自动化生产线。支持企业联合科研院所开展中药材采收初加工技术规范研究，分品种制定产地初加工的技术规程，提高中药材采收和产地初加工质量管理水平。推动医药企业将药品质量管理体系向中药材种植及初加工环节延伸，健全中药材生产质量追溯体系。鼓励企业开展中药材初加工产生的非药用部位及下脚料进行开发利用，促进提升中药材种植加工效益。（五）实施优强企业培育行动 14.着力打造链主企业。建立链主企业遴选和培育机制，支持链主企业整合药材基地、药用辅料、医药流通等资源，通过全产业链布局带动上下游协同发展，牵头组建产学研创新联合体开展科技创新攻关，对链主企业新建重点实验室、中试基地给予专项扶持。推动企业兼并重组，引导和支持中小药企依托独家品种、特色药号、祖传验方、经典方剂等资源，引进链主型战略投资者，盘活低效闲置资源，加快壮大企业规模。 15.梯度培育优质中小企业。推动中小医药企业走好专精特新发展之路，聚焦细化赛道打造独特竞争优势，新增认定一批创新型中小企业、专精特新中小企业，争创国家级 “小巨人”。引导链主企业开放生产、检测、销售渠道资源，支持中小药企承接链主 CMO（医药合同生产）代工、药材初加工、包装配套等业务，定向培育专精特新配套企业，推动大中小企业融通发展，构建 “链主引领、配套协同” 产业生态圈。（六）实施多元市场拓展行动 16.加强健康医药产业宣传推介。组织开展药械新品和重点产品发布推介和院企供需对接，推动医疗器械产业化应用和新药推广应用。依托中国消费名品、贵州消息名品名单等载体，有序培育创建医药名品方阵，打响贵州医药品牌。常态化组织医药企业参加国际性、全国性、区域性专业展览展会，不断提升“黔地多灵药”的知名度和美誉度。 17.培育健康消费新场景新业态。鼓励医药企业与电商平台、媒体等深化合作，通过多种方式为患者提供便捷高效的购药体验。鼓励医药企业终端业态从“卖药”向“卖健康服务”转变，与社区卫生服务中心、诊所等联合共建专科门诊，提供标准化诊疗方案和配套药品。支持企业拓展“中医馆+中药零售”业态，开展体质辨识、中药代煎、药膳茶饮零售等一体化服务，创新打造中药文创、道地药材体验店等场景。 18.积极拓展国际市场。支持医药企业加快融入粤港澳大湾区市场，依托香港、澳门的国际化平台拓展出海渠道。鼓励企业优势产品申报 FDA（美国食品药品监督管理局）、EMA（欧洲药品管理局）、WHO（世界卫生组织）等国际权威机构的注册认证，推动中药饮片、药食同源特色产品出海销售。支持医药企业、外贸企业、行业协会等联合搭建医药产业国际化服务平台，为企业开拓国际市场提供渠道支持和信息服务。三、组织实施各地区、相关部门按照职责分工抓好工作落实，相关任务纳入大抓产业、大抓项目、大抓招商、大抓经营主体等工作体系。省新型工业化专项组办公室加强统筹，会同省相关部门协同发力，健全重要事项会商机制，加强医药行业政企沟通对话，推动各项政策措施落到实处。充分发挥省级专项资金、产业基金的引导作用，支持金融机构创新金融产品和服务，凝聚合力加大对健康医药产业的资金支持力度。多渠道培育医药产业人才，推行校企订单式培养、柔性引才，落实高层次人才职称认定与各类人才项目申报扶持。及时总结各地各领域的先进经验和典型案例，加强宣传推广，持续营造推动健康医药产业高质量发展的良好氛围。